

Applicant:

RAMNARAYAN et al

Serial No .:

09/709,905

Conf. No.:

3606

Filed: November 10, 2000

For:

USE OF COMPUTATIONALLY DERIVED

PROTEIN STRUCTURES OF GENETIC

POLYMORPHISMS IN

PHARMACOGENOMICS FOR DRUG **DESIGN AND CLINICAL APPLICATIONS** 

Art Unit:

1631

Examiner:

Unassigned

TRANSMITTAL LETTER

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope

addressed to:

Commissioner for Patents

Washington, D.C. 20231, on this date.

08/30/01

Date

RECEIVED

SEP U 6 2001

TECH CENTER 1600/2900

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an Amendment in Response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, with paper and disk copies of the Substitute Sequence Listing, copy of the Notice to Comply and Raw Sequence Listing, and a Verified Statement that the paper and computer readable copies of the Substitute Sequence Listing are the same.

The Commissioner is hereby authorized to charge any fee, including any submitted X herewith if an attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,

HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman Registration No. 33,779

Attorney Docket No. 24737-1906C Address all correspondence to: Stephanie Seidman, Esq. HELLER, EHRMAN, WHITE & McAULIFFE LLP 4350 La Jolla Village Drive, Suite 600 San Diego, CA 92122-1246

Telephone: (858) 450-8400 Facsimile: (858) 587-5360 EMAIL: sseidman@hewm.com





TECH CENTER 1600/2900

Applicant:

RAMNARAYAN et al

Serial No.: Conf. No.: 09/709,905

3606

Filed: November 10, 2000

For:

**USE OF COMPUTATIONALLY DERIVED** PROTEIN STRUCTURES OF GENETIC

**POLYMORPHISMS IN** 

PHARMACOGENOMICS FOR DRUG **DESIGN AND CLINICAL APPLICATIONS** 

Art Unit:

1631

Examiner:

Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope

Commissioner for Patents

Washington, D.C. 20231, on this date.

08/30/01

Date

AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Responsive to the Notice to Comply and the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, please amend the above-captioned application as follows:

## IN THE SEQUENCE LISTING:

Please replace the sequence listing in the above-captioned application with the attached substitute SEQUENCE LISTING in the above-captioned application. A disk copy of the SEQUENCE LISTING accompanies this response.

## REMARKS

Any fees that may be due in connection with this paper or with this application during its entire pendency may be charged to Deposit Account No. 50-1213. If a Petition for extension of time is needed, this paper is to be considered such Petition.

Attached herewith is copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, the Substitute Sequence Listing, disk and paper copies, and a Verified Statement that the content of the paper and computer readable copies are the same. It is believed that no fee is due. However, if it is determined that a fee is due, any fees that may be due in connection with this paper or with this application during its entire pendency may be